Crohn’s Disease Therapeutics Market: Industry Analysis and Forecast (2024-2030) by Therapeutic Type and Region

Crohn’s Disease Therapeutics Market size was valued at US$ 7.47 Bn in 2023 and the total revenue is expected to grow at 5.9 % through 2024 to 2030, reaching nearly US$ 11.16 Bn.

Crohn’s Disease Therapeutics Market Overview:

Inflammatory bowel disease (IBD) is a form of the disease that affects the intestines (IBD). It causes stomach pain, severe diarrhea, exhaustion, weight loss, and starvation by inflaming your digestive tract. Crohn's disease causes inflammation in various parts of the digestive tract, depending on the individual. This inflammation frequently progresses to the bowel's deeper layers. Crohn’s Disease Therapeutics MarketTo know about the Research Methodology :- Request Free Sample Report

Crohn’s Disease Therapeutics Market Dynamics:

The rising frequency of the disease, combined with a growth in the number of pipeline medications, is likely to drive the market. Industrialization, environmental variables such as variances in sun exposure, changes in nutrition, smoking, and hereditary traits have all contributed to a rise in Crohn's disease prevalence in developing countries. Irritable bowel illness affects about 1.8 million Americans each year, according to the Centers for Disease Control and Prevention (CDC). The industry's growth is being guided by constant efforts in the development of biosimilars. One of the key advantages of biosimilars is their low cost, which has resulted in significant savings in the healthcare systems of the US. and Europe. Moreover, Increased availability of biological medicines, as a result of lower costs, can improve patient care. In the future, the sector is expected to be driven by the development of innovative biological agents and anti-cytokine agents with different mechanisms of action, as well as the use of stem cells in disease treatment. TNF agents like Infliximab and Adalimumab, for example, have shown to be effective in treating the condition. Partnerships with research institutes and the purchase of minor firms are two significant techniques used by players to achieve a stable market position. The development of novel therapy products is also a priority to boost the market expansion. For example, Johnson & Johnson one of the leading healthcare industry proclaimed in 2016 that the FDA has approved Stelara for the treatment of Crohn's disease.

Crohn’s Disease Therapeutics Market Segment Analysis:

The Non-Surgical segment is anticipated to adhere to the growth of the Crohn’s Disease Therapeutics Market. The non-surgical sub-segment is dominating the growth of the therapeutic segment in the forecast period with a market share of 49% in 2023. The non-surgical segment is further divided into subcategories such as anti-Inflammatory, Immune system suppressors, Antibiotics, Others. The anti-inflammatory segment conquered the Crohn’s disease therapeutics market with the highest market share in 2023. Anti-inflammatories are the first line of drugs treatment and are targeted effectively. During the projected period, the immune system suppressors segment is also expected to grow at a CAGR of 3.2%. Immune suppressors have been demonstrated to be both safe and effective. The segment is predicted to be driven by lower rates of mortality, hospitalization, and surgery, as well as enhanced patient quality of life. Immune system suppressors are now being developed by companies like Genentech Inc. and Celgene Corporation to treat this problem. The immune system suppressor etrolizumab, developed by Genentech Inc., is now being explored in clinical studies. This medicine showed promise in phase II clinical studies in terms of safety and efficacy. The certification of these items could aid the future growth of this business.

Crohn’s Disease Therapeutics Market Regional Segment:

In terms of revenue, North America dominated the global market in 2023. The rise of the disease is fuelled by established R&D infrastructure, the development of novel medicines, and the increased prevalence of the condition. The Crohn's and Colitis Foundation estimates that 1.6 million Americans have the disease. Further, Due to the obvious high frequency of the disease and the strong healthcare infrastructure in place, new treatment options are being developed and made available to patients. In addition, A high prevalence of Crohn's disease in the region, particularly in Canada and the US. unhealthy lifestyles such as fast food consumption and smoking habits, progressive healthcare infrastructure, and innovative healthcare solutions are all factors contributing to the growth of the market. The objective of the report is to present a comprehensive analysis of the Crohn’s Disease Therapeutics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Crohn’s Disease Therapeutics Market dynamics, structure by analyzing the market segments and project the Crohn’s Disease Therapeutics Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Crohn’s Disease Therapeutics Market make the report investor’s guide.

Crohn’s Disease Therapeutics Market Scope: Inquire before buying

Crohn’s Disease Therapeutics Market
Report Coverage Details
Base Year: 2023 Forecast Period: 2024-2030
Historical Data: 2018 to 2023 Market Size in 2023: US $ 7.47 Bn.
Forecast Period 2024 to 2030 CAGR: 5.9% Market Size in 2030: US $ 11.16 Bn.
Segments Covered: by Therapeutic Type Surgical Non-Surgical
by Distribution Channel Hospital Pharmacies Retail Pharmacies eCommerce

Crohn’s Disease Therapeutics Market, by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Crohn’s Disease Therapeutics Market Key Players

1. AbbVie Inc. 2. Allergan, Inc. 3. Bayer AG 4. Bristol-Myers Squibb 5. Boehringer Ingelheim GmbH 6. F. Hoffmann-La Roche 7. Eli Lilly and Co. 8. GlaxoSmithKline plc 9. Janssen Biotech, Inc. 10.Johnson & Johnson 11.Novartis International AG 12.Pfizer Inc. 13.Sanofi 14.Takeda Pharmaceutical Company Limited 15.Salix Pharmaceuticals 16.Gilead Sciences Inc. 17.Genentech Inc. 18.UCB India Private Limited.


1. What is the Crohn’s Disease Therapeutics Market value in 2023? Ans: The Crohn’s Disease Therapeutics Market value in 2023 was estimated as 7.47 Billion USD. 2. What is the Crohn’s Disease Therapeutics Market growth? Ans: The Crohn’s Disease Therapeutics Market is anticipated to grow with a CAGR of 5.9% in the forecast period and is likely to reach USD 11.16 Billion by the end of 2030. 3. Which Therapeutic Type segment is expected to dominate the Crohn’s Disease Therapeutics Market during the forecast period? Ans: Non-Surgical segment accounted for the largest share 49% in 2023. This is attributed to the adoption higher medications and technological investment in medical devices which are less invasive. 4. Which region is expected to dominate the Crohn’s Disease Therapeutics Market during the forecast period? Ans: North America dominated the global market in terms of revenue in 2023. Established R&D infrastructure, development of novel therapeutics, and rising prevalence of the disease are key factors contributing to its growth. 5. What is the key driving factor for the growth of the Crohn’s Disease Therapeutics Market? Ans: Key factors that are driving the Crohn’s Disease Therapeutics market growth include the Growing prevalence of the disease, along with increase in number of pipeline drugs, is expected to be a key factor driving the market.
1. Global Crohn’s Disease Therapeutics Market: Research Methodology 2. Global Crohn’s Disease Therapeutics Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Crohn’s Disease Therapeutics Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Crohn’s Disease Therapeutics Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Crohn’s Disease Therapeutics Market Segmentation 4.1. Global Crohn’s Disease Therapeutics Market, by Therapeutic Type (2023-2030) • Surgical • Non-Surgical o Anti-Inflammatory o Immune system suppressors o Antibiotics o Others 4.2. Global Crohn’s Disease Therapeutics Market, by Distribution Channel (2023-2030) • Hospital Pharmacies • Retail Pharmacies • eCommerce 5. North America Crohn’s Disease Therapeutics Market(2023-2030) 5.1 North American Crohn’s Disease Therapeutics Market, By Therapeutic Type (2023-2030) • Surgical • Non-Surgical o Anti-Inflammatory o Immune system suppressors o Antibiotics o Others 5.2 North America Crohn’s Disease Therapeutics Market, By Distribution Channel (2023-2030) • Hospital Pharmacies • Retail Pharmacies • eCommerce 5.3 North America Crohn’s Disease Therapeutics Market, by Country (2023-2030) • United States • Canada • Mexico 6. European Crohn’s Disease Therapeutics Market (2023-2030) 6.1. European Crohn’s Disease Therapeutics Market, By Therapeutic Type (2023-2030) 6.2. European Crohn’s Disease Therapeutics Market, By Distribution Channel (2023-2030) 6.3 European Crohn’s Disease Therapeutics Market, by Country (2023-2030) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Crohn’s Disease Therapeutics Market (2023-2030) 7.1. Asia Pacific Crohn’s Disease Therapeutics Market, By Therapeutic Type (2023-2030) 7.2. Asia Pacific Crohn’s Disease Therapeutics Market, By Distribution Channel (2023-2030) 7.3. Asia Pacific Crohn’s Disease Therapeutics Market, by Country (2023-2030) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Crohn’s Disease Therapeutics Market (2023-2030) 8.1. Middle East and Africa Crohn’s Disease Therapeutics Market, By Therapeutic Type (2023-2030) 8.2. Middle East and Africa Crohn’s Disease Therapeutics Market, By Distribution Channel (2023-2030) 8.3. Middle East and Africa Crohn’s Disease Therapeutics Market, by Country (2023-2030) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Crohn’s Disease Therapeutics Market (2023-2030) 9.1. South America Crohn’s Disease Therapeutics Market, By Therapeutic Type (2023-2030) 9.2. South America Crohn’s Disease Therapeutics Market, By Distribution Channel (2023-2030) 9.3 South America Crohn’s Disease Therapeutics Market, by Country (2023-2030) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 AbbVie Inc. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Allergan, Inc. 10.3 Bayer AG 10.4 Bristol-Myers Squibb 10.5 Boehringer Ingelheim GmbH 10.6 F. Hoffmann-La Roche 10.7 Eli Lilly and Co. 10.8 GlaxoSmithKline plc 10.9 Janssen Biotech, Inc. 10.10 Johnson & Johnson 10.11 Novartis International AG 10.12 Pfizer Inc. 10.13 Sanofi 10.14 Takeda Pharmaceutical Company Limited 10.15 Salix Pharmaceuticals 10.16 Gilead Sciences Inc. 10.17 Genentech Inc. 10.18 UCB India Private Limited.